-
Something wrong with this record ?
The incidence of beta-defensin 1, 2, 3 in human healthy and chronically inflamed nasal and tonsillar mucosa
Hana Pacova, Jaromir Astl, Jindrich Martinek
Language English Country Czech Republic
NLK
Free Medical Journals
from 2003 to 2013
Freely Accessible Science Journals
from 2003 to 2013
ROAD: Directory of Open Access Scholarly Resources
from 2002
- Keywords
- beta-defensins, nasal mucosa, palatine tonsil, chronic inflammation,
- MeSH
- beta-Defensins immunology isolation & purification MeSH
- Financing, Organized MeSH
- Immunohistochemistry methods utilization MeSH
- Antimicrobial Cationic Peptides immunology isolation & purification MeSH
- Palatine Tonsil physiology microbiology pathology MeSH
- Culture Techniques methods utilization MeSH
- Humans MeSH
- Nasal Polyps immunology microbiology MeSH
- Nasal Mucosa physiology microbiology pathology MeSH
- Staphylococcus aureus immunology isolation & purification MeSH
- Case-Control Studies MeSH
- Tonsillitis diagnosis immunology microbiology MeSH
- Check Tag
- Humans MeSH
The nasal and tonsillar mucosa are exposed to massive incursions of pathological microorganisms. One of the mechanisms known to prevent an invasion of pathogens is an endogenous synthesis of antimicrobial peptides, which include human beta-defensins-1, 2, 3 (HBD-1, 2, 3). The aim of this study was to demonstrate the occurrence of HBD-1, 2 and 3 in the human nasal mucosa and palatine tonsils in healthy tissues and during chronic inflammation (nasal polyposis with and without the colonization of Staphylococcus aureus and chronic tonsillitis) and to evaluate their incidence under varying conditions. Another target was to compare the occurrence of human beta-defensins in these two different entities; that is, in the nasal mucosa and in the palatine tonsil. It was assumed that the incidence of HBD-1, 2, 3 was lower in tonsils than in nasal mucosa; however, inflamed samples of tonsils and nasal mucosa showed no difference in the production of HBD-1, 2, 3. The presence of all three subfamilies of HBD was significantly lower in nasal polyps with Staphylococcus aureus positive than in the negative control.
References provided by Crossref.org
Lit.: 11
- 000
- 00000naa 2200000 a 4500
- 001
- bmc10014966
- 003
- CZ-PrNML
- 005
- 20111210175718.0
- 008
- 101207s2010 xr e eng||
- 009
- AR
- 024 7_
- $a 10.2478/v10136-009-0012-x $2 doi
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Pácová, Hana, $d 1978- $7 xx0086645
- 245 14
- $a The incidence of beta-defensin 1, 2, 3 in human healthy and chronically inflamed nasal and tonsillar mucosa / $c Hana Pacova, Jaromir Astl, Jindrich Martinek
- 314 __
- $a Inst. of Histology and Embryology, First Faculty of Medicine, Charles University, Prague 2
- 504 __
- $a Lit.: 11
- 520 9_
- $a The nasal and tonsillar mucosa are exposed to massive incursions of pathological microorganisms. One of the mechanisms known to prevent an invasion of pathogens is an endogenous synthesis of antimicrobial peptides, which include human beta-defensins-1, 2, 3 (HBD-1, 2, 3). The aim of this study was to demonstrate the occurrence of HBD-1, 2 and 3 in the human nasal mucosa and palatine tonsils in healthy tissues and during chronic inflammation (nasal polyposis with and without the colonization of Staphylococcus aureus and chronic tonsillitis) and to evaluate their incidence under varying conditions. Another target was to compare the occurrence of human beta-defensins in these two different entities; that is, in the nasal mucosa and in the palatine tonsil. It was assumed that the incidence of HBD-1, 2, 3 was lower in tonsils than in nasal mucosa; however, inflamed samples of tonsils and nasal mucosa showed no difference in the production of HBD-1, 2, 3. The presence of all three subfamilies of HBD was significantly lower in nasal polyps with Staphylococcus aureus positive than in the negative control.
- 650 _2
- $a nosní sliznice $x fyziologie $x mikrobiologie $x patologie $7 D009297
- 650 _2
- $a krční mandle $x fyziologie $x mikrobiologie $x patologie $7 D014066
- 650 _2
- $a kationické antimikrobiální peptidy $x imunologie $x izolace a purifikace $7 D023181
- 650 _2
- $a beta-defensiny $x imunologie $x izolace a purifikace $7 D023083
- 650 _2
- $a Staphylococcus aureus $x imunologie $x izolace a purifikace $7 D013211
- 650 _2
- $a nosní polypy $x imunologie $x mikrobiologie $7 D009298
- 650 _2
- $a tonzilitida $x diagnóza $x imunologie $x mikrobiologie $7 D014069
- 650 _2
- $a kultivační techniky $x metody $x využití $7 D046508
- 650 _2
- $a imunohistochemie $x metody $x využití $7 D007150
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a studie případů a kontrol $7 D016022
- 653 00
- $a beta-defensins
- 653 00
- $a nasal mucosa
- 653 00
- $a palatine tonsil
- 653 00
- $a chronic inflammation
- 700 1_
- $a Astl, Jaromír, $d 1964- $7 jn20020716588
- 700 1_
- $a Martínek, Jindřich, $d 1938-2018 $7 jn20000710438
- 773 0_
- $w MED00012667 $t Journal of applied biomedicine $g Roč. 8, č. 2 (2010), s. 81-86 $x 1214-021X
- 856 41
- $u https://jab.zsf.jcu.cz/pdfs/jab/2010/02/04.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b B 2301 $c 1249 $y 8
- 990 __
- $a 20100611141136 $b ABA008
- 991 __
- $a 20101207135124 $b ABA008
- 999 __
- $a ok $b bmc $g 750834 $s 614512
- BAS __
- $a 3
- BMC __
- $a 2010 $b 8 $c 2 $d 81-86 $m Journal of Applied Biomedicine $x MED00012667
- LZP __
- $a 2010-18/mkal